Welcome to our dedicated page for Morphosys news (Ticker: MOR), a resource for investors and traders seeking the latest updates and insights on Morphosys stock.
MorphoSys AG (MOR) is a global biopharmaceutical leader advancing innovative cancer therapies through cutting-edge research and strategic collaborations. This page serves as the definitive source for verified company announcements, clinical trial updates, and regulatory developments.
Investors and researchers will find curated news spanning clinical milestones, regulatory submissions, and strategic partnerships that shape the oncology landscape. Our updates cover essential developments including drug trial progress, intellectual property advancements, and financial performance disclosures.
All content is rigorously maintained to provide accurate, timely information without speculative commentary. For stakeholders tracking MOR's contributions to hematology and oncology treatments, this resource offers efficient monitoring of material events influencing both medical practice and investment considerations.
Bookmark this page for streamlined access to MorphoSys AG's latest developments in targeted cancer therapies and biopharmaceutical innovation. Regularly updated to reflect the company activities driving progress in global healthcare solutions.
Rhea-AI Summary
MorphoSys AG (MOR) has entered into a Business Combination Agreement with Novartis, who will submit a voluntary public takeover offer for all outstanding MorphoSys shares at a price of €68.00 per share in cash. Novartis also seeks exclusive, worldwide rights to develop and commercialize pelabresib and tulmimetostat. Additionally, MorphoSys entered into a Purchase Agreement to sell all rights related to tafasitamab to Incyte. The offer provides shareholders with a 94% premium to the one-month volume weighted average price before January 25, 2024. Novartis will provide resources to maximize pelabresib's potential and MorphoSys' Management Board and Supervisory Board unanimously support both agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.79%
Tags
-
News
Rhea-AI Summary
Incyte has entered into an asset purchase agreement with MorphoSys AG, gaining exclusive global rights to tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® and outside of the U.S. as Minjuvi®. The new agreement allows Incyte to realize significant operating efficiencies and cost synergies. Incyte will now recognize revenue and cost for all U.S. commercialization and clinical development, and MorphoSys will no longer be eligible to receive future milestone, profit split, and royalty payments. Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and is currently in Phase 3 trials for multiple indications, including first-line DLBCL, relapsed or refractory follicular lymphoma (FL), and relapsed or refractory marginal zone lymphoma (MZL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.79%
Tags
-
Rhea-AI Summary
MorphoSys AG reported preliminary Monjuvi U.S. net product sales of US$ 92.0 million and preliminary gross margin of 69% for 2023. Anticipated 2024 Monjuvi U.S. net product sales are expected to be in the range of US$ 80 to 95 million, with 2024 OpEx in the range of € 350 to 380 million and 2024 cash burn of approximately € 250 million. The company also reduced its financial liability from the collaboration with Incyte by approximately € 112 million. MorphoSys expects growth from new indications currently being investigated in Phase 3 studies. The company's CEO emphasized the potential of Monjuvi and the focus on maintaining a strong financial position in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
Rhea-AI Summary
MorphoSys AG (MOR) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
-
Rhea-AI Summary
MorphoSys AG (MOR) announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. The study demonstrated significant reductions in spleen size and symptoms, improved measures of anemia, bone marrow fibrosis, and a well-tolerated safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.25%
Tags
-
Rhea-AI Summary
MorphoSys AG (MOR) announced strong topline results from the Phase 3 MANIFEST-2 study, showing pelabresib's significant improvement in myelofibrosis patients. The combination therapy met the primary endpoint, nearly doubling SVR35 response rate, and demonstrated meaningful anemia improvement. Key secondary endpoints assessing symptom reduction and TSS showed significant improvements for intermediate-risk patients. Safety results were consistent with prior clinical trials. MorphoSys intends to submit for approval in the U.S. and Europe in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.35%
Tags
Rhea-AI Summary
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports Q3 2023 results, including Monjuvi U.S. net product sales of US$ 23.4 million. Phase 3 MANIFEST-2 topline results expected by end of November, with detailed findings in oral presentation at ASH 2023. U.S. FDA granted Fast Track designation for tulmimetostat in ARID1A-mutated endometrial cancer. Company has € 642.2 million in cash and other financial assets as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.79%
Tags
-
Rhea-AI Summary
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will release its Q3 and first nine months 2023 results on November 15, 2023, with a conference call and webcast on November 16, 2023. The Management team will present the results and outlook, followed by a Q&A session. Participants can join via phone or webcast, with a replay available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
-
Rhea-AI Summary
MorphoSys AG announced that data from the Phase 3 MANIFEST-2 trial of pelabresib will be presented at the ASH Annual Meeting. The trial evaluated the investigational BET inhibitor in combination with the JAK inhibitor ruxolitinib in myelofibrosis patients. The company will also share topline results from the study in the coming weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
Rhea-AI Summary
MorphoSys reports preliminary Q3 2023 net product sales of $23.4 million for Monjuvi in the US. Full year 2023 sales expected to be $85-95 million with a gross margin of approximately 75%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
Morphosys Ag